LYRA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.72 USD | -8.70% |
|
-9.06% | -9.92% |
| Mar. 22 | Lyra Therapeutics Files $300 Million Mixed Shelf Offering | MT |
| Mar. 21 | Lyra Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Chart calendar Lyra Therapeutics, Inc.
30176099637834c7073.spTq6pFbCl8M5kWMsLx7jBS58RjGxcN-V8lAVLSaqWc.gtGtrOcETBpLryvn1fIf_EHxxHGUoq9MFZ4EZdrjmzLq3J6ApgNjGDyLcQ~04ff6cc32e8f4bcd942a3ef6c22594cd
Upcoming events on Lyra Therapeutics, Inc.
Past events on Lyra Therapeutics, Inc.
| 2024-03-21 04:01 pm | Q4 2023 Earnings Release |
| 2023-11-29 09:30 am | Piper Sandler Healthcare Conference |
| 2023-11-16 08:30 am | Jefferies London Healthcare Conference |
| 2023-11-07 04:01 pm | Q3 2023 Earnings Release |
| 2023-09-29 | American Rhinologic Society Meeting |
| 2023-09-26 02:45 pm | Cantor Global Healthcare Conference |
| 2023-09-13 02:00 pm | H.C. Wainwright Global Investment Conference |
| 2023-09-12 08:00 am | LYR-220 BEACON Phase 2 Clinical Study Results Call |
| 2023-08-08 04:01 pm | Q2 2023 Earnings Release |
| 2023-07-18 10:00 am | William Blair Virtual Biotechnology Conference |
| 2023-06-13 08:30 am | Annual General Meeting |
| 2023-06-07 10:30 am | Jefferies Global Healthcare Conference |
| 2023-05-12 07:00 am | Q1 2023 Earnings Release |
| 2023-05-10 07:35 pm | Bank of America Healthcare Conference |
| 2023-03-29 04:06 pm | Q4 2022 Earnings Release |
| 2022-11-17 11:25 am | Jefferies London Healthcare Conference |
| 2022-11-15 04:10 pm | Stifel Healthcare Conference |
| 2022-11-14 | Q3 2022 Earnings Release (Projected) |
| 2022-09-14 12:00 pm | H.C. Wainwright Global Investment Conference |
| 2022-09-10 02:14 pm | American Rhinologic Society Meeting - Health Disparities, Disease Burden, and Patient Outcomes |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 | 0,00 0,00 - | 0,29 1,01 -71.76% | 1,36 4,84 -71.84% | 1,56 1,74 -10.41% | 1,38 |
|
EBITDA Million USD | Released Forecast Spread | 0,00 | -22,1 -19,6 -12.98% | -42,6 -41,8 -2.04% | -53,9 -52,8 -2.17% | 0,00 -73,3 - | -59,5 |
|
EBIT Million USD | Released Forecast Spread | 0,00 | -22,2 -22,1 -0.33% | -43,6 -40,7 -7.28% | -55,0 -53,4 -3.03% | -67,1 -68,9 2.53% | -71,2 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 0,00 | -22,1 -21,2 -4.34% | -43,5 -39,9 -9.12% | -55,3 -54,5 -1.43% | -62,6 -65,1 3.85% | -68,5 |
|
Net income Million USD | Released Forecast Spread | 0,00 | -22,1 -21,9 -1.1% | -43,5 -40,6 -7.24% | -55,3 -53,3 -3.74% | -62,7 -65,2 3.8% | -68,6 |
|
EPS USD | Released Forecast Spread | -2,37 | -2,59 -2,01 -28.86% | -3,35 -3,12 -7.37% | -1,83 -1,78 -2.81% | -1,26 -1,31 3.69% | -1,01 |
| Announcement Date | 06/03/20 | 09/03/21 | 09/03/22 | 29/03/23 | 21/03/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,27 1,13 -75.91% | 5,37 1,25 329.36% | 0,41 1,91 -78.72% | 0,36 0,14 164.61% | 0,01 0,19 -94.09% | 0,41 0,16 157.05% | 0,46 0,14 235.11% | 0,54 0,37 46.39% | 0,15 0,39 -62.45% | 0,35 | 0,35 | 0,35 | 0,34 | 0,00 |
|
EBITDA Million USD | Released Forecast Spread | -14,5 -13,1 -11.2% | -13,6 -15,0 9.38% | -21,4 | |||||||||||
|
EBIT Million USD | Released Forecast Spread | -13,6 -10,4 -31.48% | -7,03 -13,3 47.09% | -14,5 -11,9 -22.16% | -14,8 -15,0 1.44% | -13,8 -15,1 8.46% | -17,3 -14,8 -16.66% | -16,5 -17,7 6.52% | -16,8 -16,6 -1.13% | -16,5 -18,7 12.12% | -17,5 | -18,1 | -18,6 | -19,3 | -19,0 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -13,6 -10,3 -31.57% | -7,01 -12,6 44.53% | -14,5 -10,8 -33.51% | -14,8 -16,0 7.77% | -14,2 -15,0 5.34% | -16,2 -14,5 -12.21% | -15,6 -17,4 10.2% | -15,6 -16,0 2.56% | -15,1 -16,9 10.45% | -16,9 | -17,5 | -18,1 | -18,6 | -19,0 |
|
Net income Million USD | Released Forecast Spread | -13,6 -10,3 -31.57% | -7,01 -13,3 47.16% | -14,5 -11,9 -22.06% | -14,8 -15,0 1.75% | -14,2 -15,1 5.82% | -16,3 -14,5 -12.31% | -15,6 -17,4 10.13% | -15,7 -16,0 2.46% | -15,2 -18,2 16.63% | -16,9 | -17,5 | -18,1 | -18,6 | -19,0 |
|
EPS USD | Released Forecast Spread | -1,05 -0,79 -32.91% | -0,54 -0,92 40.98% | -0,43 -0,36 -19.44% | -0,40 -0,44 8.68% | -0,36 -0,41 13.04% | -0,44 -0,37 -20.55% | -0,36 -0,42 14.96% | -0,27 -0,32 15.09% | -0,19 -0,32 39.68% | -0,27 | -0,25 | -0,25 | -0,25 | -0,24 |
| Announcement Date | 09/03/22 | 10/05/22 | 09/08/22 | 08/11/22 | 29/03/23 | 12/05/23 | 08/08/23 | 07/11/23 | 21/03/24 | - | - | - | - | - |
| Today 04:05 pm | QIAGEN N.V.: Q1 2024 Earnings Release |
| 2024-04-29 | CRISPR THERAPEUTICS AG: Q1 2024 Earnings Release (Projected) |
| 2024-04-30 | DYNE THERAPEUTICS, INC.: Q1 2024 Earnings Release (Projected) |
| 2024-04-30 | PROTAGONIST THERAPEUTICS, INC.: Q1 2024 Earnings Release (Projected) |
| 2024-04-30 | EDITAS MEDICINE, INC.: Q1 2024 Earnings Release (Projected) |
| 2024-04-30 | AZENTA, INC.: Q2 2024 Earnings Release (Projected) |
| 2024-05-01 06:30 am | UNITED THERAPEUTICS CORPORATION: Q1 2024 Earnings Release |
| 2024-05-01 06:30 am | BIO-TECHNE CORPORATION: Q3 2024 Earnings Release |
| 2024-05-01 07:00 am | ALKERMES PLC: Q1 2024 Earnings Release |
| 2024-05-01 | VIR BIOTECHNOLOGY, INC.: Q1 2024 Earnings Release |
Past sector events for Lyra Therapeutics, Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- LYRA Stock
- Calendar Lyra Therapeutics, Inc.
